

NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

This notice is given by Bio-Gene Technology Limited ("the **Company**") (ASX:BGT) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**). For the purposes of section 708A(6) of the Act, the Company states that:

- (a) On 11 September 2023 the Company issued 5,952,381 fully paid ordinary shares in the Company without disclosure to investors under Part 6D.2 of the Act.
- (b) This notice is being given under section 708A(5)(e) of the Act.
- (c) As at the date of this notice, the Company has complied with:
 - i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - ii) section 674 of the Act.
- (d) As at the date of this notice, the Company is not aware of any information required to be disclosed for the purposes of section 708A(6)(e) of the Act, being information:
 - i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of the ASX; and
 - ii) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - the rights and liabilities attaching to the ordinary shares of the Company.

Approved for release by the Board.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Tim Grogan, CEO

E: <u>bgt.info@bio-gene.com.au</u>

M: 0438 655 452

Rod Valencia, CFO

E: bgt.info@bio-gene.com.au

M: 0450 218 832

Media & Investor Relations:

Adrian Mulcahy, Investor Relations

E: adrian.mulcahy@automicgroup.com.au

M: 0438 630 422

Tristan Everett, Media Relations

E: tristan.everett@automicgroup.com.au

M: 0403 789 096



About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across Crop Protection, Grain Storage, Public Health and Consumer Products. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and pest management solutions.

FLAVOCIDE® is a nature-identical beta-triketone molecule produced synthetically by a chemical process. It is covered by Bio-Gene patents for use as an insecticide and has demonstrated significant activity against a range of insect pests. Bio-Gene is the Owner in Australia of FLAVOCIDE®, registered Trademark 1714598.